Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for…
Posted: October 2, 2019 at 2:42 am
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy. Results from the anaplastic lymphoma kinase (ALK) cohort will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress on Monday, September 30 from 9:15 9:30 a.m. CEST (Abstract LBA81 PR) and were also part of the official ESMO press program.
Obtaining tumor tissue for biomarker testing can be a challenge in many people with cancer and, as a result, some may not receive optimal treatment for their disease, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. BFAST is the first trial to show that by using a blood-based next-generation diagnostic, it is possible to identify the ALK mutation in people with non-small cell lung cancer using a blood draw alone, which means that more people could potentially benefit from Alecensa.
Foundation Medicine is pleased to partner with Roche on this study, a first-of-its-kind, pivotal trial that directly demonstrates the clinical utility of using our comprehensive blood-based assay, FoundationOne Liquid, to detect specific fusions and match NSCLC patients with first-line treatment, said Brian Alexander, M.D., chief medical officer of Foundation Medicine. Validated and comprehensive liquid biopsy tests are critical to help physicians find the best possible treatment approach for patients with advanced cancer and for whom tissue testing isnt feasible. Identifying ALK fusions can be particularly challenging and these data demonstrate that FoundationOne Liquid can accurately predict which patients can respond to therapy.
The BFAST study used FoundationOne Liquid, Foundation Medicines comprehensive liquid biopsy test, which detects the four main classes of genomic alterations, microsatellite instability (MSI) and select fusions including ALK in circulating tumor DNA (ctDNA) from a blood draw. These data demonstrate that the FoundationOne Liquid assay can help to test and identify a broader population of people with advanced NSCLC who may benefit from Alecensa, for whom current diagnostic tests are not suitable, such as for those who cannot provide tissue samples due to insufficient or absent tumor tissue, or where tissue diagnostics are not available, and validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK-positive NSCLC.
In the study, 87.4% (95% CI: 78.5-93.5) of people with advanced NSCLC who were identified by the FoundationOne Liquid biopsy assay to have ALK fusions had a confirmed response to treatment with Alecensa (overall response rate; ORR) as measured by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). This is consistent with the ORR for Alecensa observed in the pivotal Phase III ALEX trial, which identified people using tissue-based testing. When measured using an Independent Review Facility per RECIST v1.1, the confirmed ORR was numerically higher at 92.0% (95% CI: 84.1-96.7). Median progression free-survival (PFS) and duration of response (DoR) were not reached after a median follow-up of 12.6 months. The safety profile of Alecensa was consistent with prior clinical trials and post-marketing experience, with no new safety signals observed.
About the BFAST study
BFAST (Blood First Assay Screening Trial) (NCT03178552) is a Phase II/III global, multi-center, open-label, multi-cohort study evaluating the safety and efficacy of targeted therapies or immunotherapies as single agents or in combination in people with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or be tumor mutational burden (TMB)-positive as identified by blood-based NGS ctDNA assays. The Alecensa ALK-positive cohort is the first to readout, with other cohorts due to follow. The primary endpoint for the Alecensa ALK-positive cohort of the BFAST study is confirmed investigator (INV)-assessed ORR. Secondary endpoints include: independent review facility (IRF)-assessed ORR, DoR (INV and IRF), PFS (INV and IRF), overall survival (OS) and safety.
About lung cancer
According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2019, and NSCLC accounts for 80-85% of all lung cancers. It is estimated that approximately 60% of lung cancer diagnoses in the United States are made when the disease is in the advanced stages.
About Alecensa (alectinib)
Alecensa is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Alecensa U.S. Indication
Alecensa is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Important Safety Information
Everyone reacts differently to treatment with Alecensa. Its important to know the most serious and most common side effects with Alecensa.
A doctor may lower the dose or stop treatment with Alecensa if any serious side effects occur. Patients taking Alecensa should contact their doctor right away if they have any of the following side effects.
Alecensa may cause serious side effects, including:
Liver problems (hepatotoxicity). Alecensa may cause liver injury. A doctor will do blood tests at least every 2 weeks for the first 3 months and as needed during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they experience any of the following signs and symptoms:
Lung problems. Alecensa may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. Symptoms may be similar to those symptoms from lung cancer. Patients taking Alecensa should tell their doctor right away if they have any new or worsening symptoms, including:
Kidney problems. Alecensa may cause severe or life-threatening kidney problems. Tell your healthcare provider right away if you have a change in the amount or color of your urine, or if you get new or worsening swelling in your legs or feet.
Slow heartbeat (bradycardia). Alecensa may cause very slow heartbeats that can be severe. A doctor will check a patients heart rate and blood pressure during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they feel dizzy, lightheaded, or faint during treatment with Alecensa. Patients taking Alecensa should tell their doctor if they take any heart or blood pressure medicines.
Muscle pain, tenderness, and weakness (myalgia). Muscle problems are common with Alecensa and can be severe. A doctor will do blood tests at least every 2 weeks for the first month and as needed during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they have any new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.
Before taking Alecensa, patients should tell their doctor about all medical conditions, including if they:
Patients taking Alecensa should tell their doctor about all the medicines they take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.
Patients taking Alecensa should avoid spending time in the sunlight during treatment with Alecensa and for seven days after the final dose of Alecensa. Patients taking Alecensa may burn more easily and get severe sunburns. Patients taking Alecensa should use sunscreen and lip balm with a SPF 50 or greater to help protect against sunburn.
The most common side effects of Alecensa include:
These are not all of the possible side effects of Alecensa. For more information, patients should ask their doctor or pharmacist. Patients should call their doctor for medical advice about side effects.
Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Patients and caregivers may also report side effects to Genentech at (888) 835-2555.
Please see additional Important Safety Information in full Prescribing Information, including Patient Information.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company, a member of the Roche Group, offers a full suite of comprehensive genomic profiling tests to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
For more information, please visit http://www.foundationmedicine.com or follow Foundation Medicine on Twitter (@FoundationMedicineATCG).
About Genentech in Lung Cancer
Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
- Gene Therapy | Doctor | Patient.co.uk [Last Updated On: May 23rd, 2015] [Originally Added On: May 23rd, 2015]
- Gene Therapy | Doctor | Patient [Last Updated On: June 9th, 2015] [Originally Added On: June 9th, 2015]
- Dr Rajiv Desai Blog Archive GENE THERAPY [Last Updated On: August 23rd, 2015] [Originally Added On: August 23rd, 2015]
- Local Doctor Leads Study Of Gene Therapy Treatment For ... [Last Updated On: March 19th, 2016] [Originally Added On: March 19th, 2016]
- Breast Cancer Risk Factors: Genetics [Last Updated On: August 24th, 2016] [Originally Added On: August 24th, 2016]
- Worlds Leading Biomarkers Congress | CPD Points ... [Last Updated On: September 22nd, 2016] [Originally Added On: September 22nd, 2016]
- Why the super-rich are ploughing billions into the booming 'immortality industry' - Evening Standard [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- What to Know About Charlie Gard, the Terminally Ill Baby Trump Wants to Help - TIME [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Cancer treatment is swiftly moving toward individualized molecular and genetic tools that Sparrow Cancer Center's ... - City Pulse [Last Updated On: July 7th, 2017] [Originally Added On: July 7th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer - ABC News [Last Updated On: July 7th, 2017] [Originally Added On: July 7th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer | KRQE ... - KRQE News 13 [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer - The ... - The Mainichi [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Charlie Gard: Medical experts weigh in on case of terminally-ill baby - The Independent [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- High-tech solutions top the list in the fight against eye disease - Engadget [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
- 'Prehab' therapy helps cancer patients prepare for treatment - KTBS [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
- Baby Charlie remains on life support as parents fight doctors for experimental treatment - CBC.ca [Last Updated On: July 13th, 2017] [Originally Added On: July 13th, 2017]
- Novel cancer treatment wins endorsement of FDA advisers - Washington Post [Last Updated On: July 13th, 2017] [Originally Added On: July 13th, 2017]
- Ocean Springs parents fight to save 3-year-old daughter from fatal genetic condition - WGNO [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- US doctor who wanted to treat Charlie Gard had 'financial interest' says Great Ormond Street - Metro [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- New cancer therapy in clinical trial at Nebraska Medical Center has ... - Omaha World-Herald [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- Scientists successfully doctor human embroyo - Examiner Enterprise [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- WBZ-TV Riders Take On Pan-Mass Challenge - CBS Boston / WBZ [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Gene editing breakthrough: Perspective from a geneticist and a pastor - WTSP 10 News [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Indian-origin doctor helps gene editing of human embryos - Times of India [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- New Gene Therapy for Vision Loss Proven Safe in Humans ... [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Springfield Mom Works to Raise Awareness after Son Diagnosed with Rare Genetic Disorder - KSMU Radio [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
- Cancer's Newest Miracle Cure - TIME [Last Updated On: August 10th, 2017] [Originally Added On: August 10th, 2017]
- Families with kids with Jordan's Syndrome meet for study to learn more about rare gene mutation - FOX 5 DC [Last Updated On: August 11th, 2017] [Originally Added On: August 11th, 2017]
- Springfield Mom Works to Raise Awareness after Son Diagnosed with Rare Genetic Disorder - KRCU [Last Updated On: August 11th, 2017] [Originally Added On: August 11th, 2017]
- Exclusive interview with Discovery's First in Human sickle cell ... - Monsters and Critics.com [Last Updated On: August 18th, 2017] [Originally Added On: August 18th, 2017]
- DHK - Representative Chris Walsh, 66, non-Hodgkin lymphoma (a white blood cell cancer), Framingham, with Dr ... - WEEI.com [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- Life Lessons: Next generation testing - WFMZ Allentown [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- Potential therapy for eye condition - WTAJ [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- New 3D-drug screening aims to ease economic burden of rare muscle diseases - Medical Xpress [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
- Doctor on new cancer treatment: 'genetically engineered, tumor-killing factory' - The Business Journal [Last Updated On: August 23rd, 2017] [Originally Added On: August 23rd, 2017]
- Baltimore 5K Aims to Raise Awareness about Sickle Cell Disease - Afro American [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Stanford Center Hopes to Take Stem Cell and Gene Therapies to a New Level - Sickle Cell Anemia News [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion - Los Angeles Times [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Man describes new FDA-approved gene therapy for leukemia that changed his life - fox4kc.com [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- First gene therapy to treat cancer gets FDA approval; UM only Michigan hospital to use it - Detroit Free Press [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- Why the federal government urgently needs to fund more cancer research - Los Angeles Times [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV - GeekWire [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- UTSA Presidential Lecture featuring Leonard Pinchuk - UTSA Today [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- South Bend man a 'walking miracle' after cancer treatment breakthrough - South Bend Tribune [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- Gene therapy - Doctor.ndtv.com [Last Updated On: May 18th, 2018] [Originally Added On: May 18th, 2018]
- what is gene therapy? - Bluebird Bio [Last Updated On: May 24th, 2018] [Originally Added On: May 24th, 2018]
- Oncotype DX: Genomic Test to Inform Breast Cancer Treatment [Last Updated On: September 29th, 2018] [Originally Added On: September 29th, 2018]
- Gene Therapy: The Future of Vision Treatment [Last Updated On: February 21st, 2019] [Originally Added On: February 21st, 2019]
- Gene Therapy Questions | FAQs - Dana-Farber/Boston ... [Last Updated On: April 22nd, 2019] [Originally Added On: April 22nd, 2019]
- Gene therapy might be a cure for "bubble boy disease ... [Last Updated On: April 24th, 2019] [Originally Added On: April 24th, 2019]
- Xconomy: SMA Moment: Will Gene Therapy Shift Treatment ... [Last Updated On: May 2nd, 2019] [Originally Added On: May 2nd, 2019]
- A Study to Evaluate the Efficacy and Safety of Factor IX ... [Last Updated On: May 26th, 2019] [Originally Added On: May 26th, 2019]
- Targeted Therapy | Treating Mesothelioma - Mesothelioma Hub [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Why the focus of autism research is shifting away from searching for a 'cure' - NBCNews.com [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Here's What Happened to Dr. Sharpe on 'New Amsterdam' Details! - Distractify [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Gene therapy drug priced at $2 million saves North Carolina babys life - WTKR News 3 [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Three to be honored as Distinguished Clay High School Alumni - Press Publications Inc. [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Beyonc's father Mathew Knowles has breast cancer: Here's what you need to know about the disease in men - Yahoo Lifestyle [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- Study Measures Prognosis for Breast Cancer Patients with High 21-gene Recurrence Score Receiving Adjuvant Chemotherapy Plus Endocrine Therapy -... [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- Beyoncs father diagnosed with breast cancer - Houston Chronicle [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- What one doctor thinks about drug shortages and how to solve them - STAT [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- The facts about breast cancer awareness | News - The Albany Herald [Last Updated On: October 8th, 2019] [Originally Added On: October 8th, 2019]
- Metastatic Breast Cancer: What You Should Know - University of Michigan Health System News [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- John Geyman on the Failure of Obamacare the Medical Industrial Complex and the Single Payer Solution - Corporate Crime Reporter [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Quebec to cover revolutionary cancer treatment for types of leukemia and non-Hodgkins lymphoma - CTV News [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Deepak Chopra Has Never Been Sick - The New Yorker [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Daughter drew inspiration from mom in battle with breast cancer, stresses early detection - Gainesville Daily Register [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Cleft palate or lip is one of the most common birth defects worldwide, but do you know what it is? - ABC News [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Pearland family fighting to get $2.1 million drug for toddler with rare genetic disease - KHOU.com [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Gene-Therapy Treatment Could Help People with Macular Degeneration - Healthline [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- A Netflix Series Explores the Brave New World of Crispr - WIRED [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Save your child from paediatric cancer: Know what to look out for - TheHealthSite [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- The 'Magic' Behind Every Successful Blockbuster Drug - DailyWealth [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- $2.1 million drug approved for Pearland toddler with rare genetic disease - KHOU.com [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular... [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Why Are More Black Women Dying From the Most Common Reproductive Cancer? - Mother Jones [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- 5 Biotech and Pharmaceutical Innovation Trends in 2019 - BioSpace [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- Breast Cancer in Men | Outlook - Big Bear Grizzly [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]